Alloy / Lash & Brow Serum Rx
BIMATOPROST 0.03% — GENERIC LATISSE
The best page Alloy publishes and the only one that is not compounded: an FDA-approved generic named against its brand, at its approved concentration, with a real fill size and the first citations this company has printed. Two problems — the three-month supply is ten weeks by the manufacturer's own applicator count, and the periorbital fat atrophy on the approved label is mentioned nowhere.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Read about prostaglandin-associated periorbitopathy before you start — it is on this drug's own FDA label and nowhere on this page.
The verdict
This is the best page Alloy publishes, and the reason is structural: it is the only product in their range that is not compounded. Bimatoprost 0.03% is an FDA-approved drug for eyelash hypotrichosis, the page says 'FDA Approved' and means it, names the brand equivalent — generic Latisse — three times over, publishes the concentration, publishes a 5 ml fill size, and mentions that sterile disposable applicators come with it, which is the detail that shows somebody read the label. It even carries citations, author and year, which is the first time this company has cited anything at all.
It is worth pausing on how neatly that lines up. Alloy's four compounded products score 58, 59, 59 and 65. The one manufactured, approved generic scores highest. The difference is not effort or intention — it is that when you dispense an approved drug, the concentration, the fill size, the applicator count and the label all already exist, and the page's job shrinks to not contradicting them.
Which it then does, on the arithmetic. Alloy sells one 5 ml bottle as 'a three-month supply' at $175. A 5 ml bottle of this drug contains 140 sterile applicators, and the label directs one applicator per eyelid — two a night for both eyes. That is 70 nights. Ten weeks, not twelve, and that is before you use any of it on the eyebrows, which this page also markets it for and which would consume the bottle faster still.
And the specific risk this drug is known for is absent. Bimatoprost causes prostaglandin-associated periorbitopathy — orbital fat atrophy, deepening of the upper eyelid sulcus, eyelid ptosis — and it does so more often than the other prostaglandin analogues. It is on Latisse's own FDA postmarketing label. The words periorbital, fat atrophy, sulcus, sunken and hollow appear zero times on this page. The FAQ does at least ask 'Can Lash & Brow Serum Rx change my eye color?' and 'What side effects should I look out for?', which is more than the estriol pages manage — but the answers are rendered by script and are not in the page we can read, and the visible copy names no risk at all.
- The only Alloy product that is a manufactured, FDA-approved drug rather than a compounded preparation.
- States 'FDA Approved' accurately, and names the brand equivalent — generic Latisse — plainly.
- Publishes the concentration: bimatoprost 0.03%, the approved strength.
- Publishes the fill size: one 5 ml bottle.
- Mentions that sterile disposable applicators are included, which is how the label directs it to be used.
- Carries citations — Carruthers 2016, Fagien 2013 — the first this company has printed on any product page.
- The FAQ asks 'Can it change my eye color?' and 'What side effects should I look out for?' — real safety questions, which the estriol pages never pose.
- Timelines of four to eight weeks for early change and sixteen weeks for full effect are consistent with the approved label.
- $0 unlimited physician access, free delivery and HSA/FSA eligibility included.
- 'A three-month supply' is 70 nights by the label's own count of 140 applicators at two per night.
- Marketed for brows as well as lashes, which would consume the bottle faster still.
- Eyebrow use is off-label; the approval the 'FDA Approved' badge refers to covers eyelashes.
- Prostaglandin-associated periorbitopathy — orbital fat atrophy, deepened eyelid sulcus, ptosis — appears nowhere, though it is on the drug's own label.
- Iris pigmentation is not named in the visible copy; only the FAQ question alludes to it.
- No pregnancy content, for the fifth Alloy page in a row.
- The safety FAQ answers are rendered by script and absent from the readable page.
- The citations give author and year with no journal or title.
- 'Almost 40% of women will experience hair loss during and after menopause' is unsourced.
Every active, assessed
- Bimatoprost0.03%
Prostaglandin F2α analogue — prolongs the anagen growth phase, increases follicle size and melanin content
- BENCHMARK
- 0.03% is the FDA-approved concentration for eyelash hypotrichosis
- ASSESSMENT
- The approved drug at the approved strength, correctly identified against its brand. Real evidence, a real label, a real applicator system. The concerns are not about what it is but about what the page leaves out: periorbital fat atrophy, iris pigmentation, and the fact that eyebrow use — heavily marketed here — is not part of the approval this page's badge refers to.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| BimatoprostProstaglandin F2α analogue — prolongs the anagen growth phase, increases follicle size and melanin content | 0.03% | 0.03% is the FDA-approved concentration for eyelash hypotrichosis | The approved drug at the approved strength, correctly identified against its brand. Real evidence, a real label, a real applicator system. The concerns are not about what it is but about what the page leaves out: periorbital fat atrophy, iris pigmentation, and the fact that eyebrow use — heavily marketed here — is not part of the approval this page's badge refers to. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%80/100
An FDA-approved drug at its approved concentration for its approved indication, with a genuine trial base and, for the first time from this company, named citations. Held back because those citations give author and year but no journal or title, because the 40% menopausal hair loss figure is unsourced, and because the eyebrow indication marketed throughout is off-label — Latisse's approval covers eyelashes.
- FORMULATION INTEGRITYWEIGHT 20%82/100
Nothing to formulate, and that is the point. This is a manufactured generic dispensed as itself, so the concentration, the vehicle, the sterility and the applicator system are the approved product's rather than a compounder's. Alloy publishes the concentration, the 5 ml volume and the inclusion of sterile single-use applicators, which is the correct level of detail for this drug.
- DISCLOSUREWEIGHT 15%46/100
Comfortably the best in the Alloy range: approved status stated accurately, brand equivalent named, concentration and fill size published, applicators mentioned, two genuine safety questions in the FAQ, and the company's first citations. Held down because the visible copy names no risk whatsoever — no iris pigmentation, and no periorbital fat atrophy despite it being on this drug's own label and more frequent with bimatoprost than its alternatives — because there is no pregnancy content for the fifth page running, and because the stated supply duration contradicts the manufacturer's applicator count.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. The relevant effects here are ocular and periorbital rather than dermatological, and they develop over months — conjunctival hyperaemia, lid pigmentation and sulcus deepening are what a long panel would need to watch for.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not applicable. This is an ophthalmic solution applied with an applicator, not a cosmetic base.
- COST PER APPLICATIONWEIGHT 10%44/100
$175 for 5 ml presented as $58 a month across three months. At the label's own applicator count the bottle is 70 nights, which makes the real rate nearer $75 a month for lashes alone and higher again if the brows are treated as the page suggests. Generic bimatoprost is widely available for less, and the unlimited physician access included is a genuine offset — but the headline monthly figure rests on a supply claim that does not survive checking.
What it is
Generic Latisse — bimatoprost ophthalmic solution 0.03% — prescribed after an online intake reviewed by a menopause-specialised physician, and applied once nightly to the upper lash line with a sterile disposable applicator. One 5 ml bottle at $175, presented as $58 a month across three months, with unlimited physician access, free delivery and HSA/FSA eligibility included.
The one Alloy product that is not compounded, and it shows
Four Alloy reviews have turned on the same absences: no concentration, no fill size, no dose, no regulatory status, no safety section under the heading marked Safety Information. This page supplies four of those five without apparent effort.
Bimatoprost 0.03% is stated. The 5 ml bottle is stated. The sterile applicators are mentioned — a small thing that signals somebody read the label, because the applicator system is how this drug's dose is controlled. 'FDA Approved' appears as a badge and is, for once in this register, accurate. And the brand equivalent is named openly: generic Latisse, three times over.
When a company dispenses an approved drug as itself, the concentration, the vehicle, the sterility, the applicator count and the full prescribing information all already exist, and the marketing page's job shrinks to not contradicting them. Alloy's four compounded products score 58, 59, 59 and 65. This one scores 69. The gap is not diligence — it is that a compounded preparation obliges a company to publish things it would rather not, and an approved generic does the publishing for it.
Five products from one company. The only one that is a manufactured, FDA-approved drug scores highest; the four compounded preparations cluster beneath it. All four compounded pages carry a Safety Information section containing a product description.
Ten weeks, sold as twelve
Here is the arithmetic, and it is the manufacturer's, not ours.
- A 5 ml bottle of this drug is supplied with 140 sterile applicators.
- The label directs one drop on one applicator per upper eyelid, and a fresh applicator for the other eye.
- That is two applicators per night for both eyes.
- 140 divided by 2 is 70 nights — ten weeks.
Alloy bills one 5 ml bottle as a three-month supply at $175. The applicator count that comes in the box supports ten weeks for eyelashes alone. The page also markets brow application, which is additional use from the same bottle and is not counted here.
The gap matters more than twenty nights sounds, because it moves the real price. At ten weeks a bottle, $175 is nearer $75 a month than $58 — and that is for lashes only. This page's whole proposition is lashes and brows together, and brow application draws on the same 5 ml.
One review ago we praised Alloy's tretinoin cream for publishing 30 grams and a pea-sized nightly dose, because it made a supply claim checkable for the first time — and it checked out. This is the second Alloy claim we have been able to verify, and it does not. Publishing enough detail to be audited is the right instinct either way; it just means the audit sometimes fails.
The thing this drug is known for is not on the page
Bimatoprost is a prostaglandin analogue, and prostaglandin analogues cause a recognised cluster of periorbital changes: orbital fat atrophy, deepening of the upper eyelid sulcus, enophthalmos and eyelid ptosis. It has a name — prostaglandin-associated periorbitopathy — and bimatoprost is associated with it more frequently than the other drugs in its class.
This is not an obscure signal. It is on Latisse's own FDA postmarketing label, which lists periorbital and lid changes including periorbital fat atrophy and deepening of the eyelid sulcus. It can appear within a month of starting, and it is generally reversible once the drug is stopped.
Searched across this page: periorbital, fat atrophy, sulcus, sunken, hollow — zero mentions each. Iris and pigment, zero. Glaucoma and intraocular pressure, zero.
Alloy's M4 Eye Cream Rx, reviewed two entries ago at $90, is sold to treat periorbital crepiness and restore firmness around the eye. This product, from the same company to the same customer, carries a labelled risk of periorbital fat atrophy and a deepened upper eyelid sulcus. Neither page mentions the other's effect. We are not suggesting the two cancel out or compound — nobody has studied that — only that a customer buying both from one prescriber deserves to have it raised once.
In fairness, this page does better than its siblings here. The FAQ contains 'Can Lash & Brow Serum Rx change my eye color?' and 'What side effects should I look out for?' — two real questions, precisely the right ones, and the estriol pages never asked anything comparable. The answers are rendered by script and do not appear in the page source we can read, so we cannot report what they say. That the questions are being asked is genuine progress; that the visible copy names no risk at all is still the finding.
One badge, two indications
The page is titled Lash & Brow Serum Rx, markets 'thicker, fuller brows' in its opening sentence, and includes an FAQ asking whether it can be used on both. It also carries an 'FDA Approved' badge.
Bimatoprost's approval for cosmetic use covers eyelash hypotrichosis. Eyebrow application is off-label — a common, defensible and widely practised off-label use, with some supporting literature, but off-label nonetheless. The badge is accurate for one of the two uses on the page and is not qualified.
Ro handled precisely this situation well two reviews ago: it stated on the page that low-dose isotretinoin was off-label, that the FDA had not approved that regimen, and that off-label prescribing is nonetheless accepted practice supported by evidence. Three sentences. Alloy needs the same three here.
If you are considering it
- Read about prostaglandin-associated periorbitopathy first. It is on the drug's label, it is more common with this molecule than its alternatives, and it is usually reversible if you stop.
- If you have glaucoma or ocular hypertension, or use prostaglandin eye drops already, speak to an ophthalmologist before starting.
- Budget for a bottle roughly every ten weeks, not twelve — and sooner if you are treating brows.
- Understand that the brow use is off-label, whatever the badge says.
- Use a fresh sterile applicator for each eye, as supplied. Do not apply to the lower lash line.
- Watch for lid darkening and any change in the appearance of the upper lid crease, and raise both promptly.
- If there is any possibility of pregnancy, ask — the page says nothing.
- Expect early change at four to eight weeks and the full effect at sixteen, which is what the label supports.
Where we stand
At 69 this is the highest-scoring Alloy product and the only one we have not marked with caution, and both facts trace to the same cause: it is the one thing in their range that is a manufactured, approved medicine rather than a compounded preparation. The page states its regulatory status correctly, names its brand equivalent, publishes its concentration and its volume, and cites two papers. Every one of those is a first for this company, and none of them required Alloy to do anything except not obscure what the manufacturer already established.
It is conditional rather than recommended for two specific things. A bottle sold as three months is ten weeks by the applicator count in its own box, which moves the real monthly price by about a third. And the periorbital fat atrophy that this drug is genuinely known for — on its own label, more frequent with bimatoprost than with its alternatives — is not mentioned anywhere a reader can see, by a company that also sells them a cream for periorbital hollowing.
Correct the supply figure to ten weeks, or price it accordingly. Put one sentence about the eyelid sulcus in the visible copy rather than behind a script. Qualify the badge for brow use, as Ro already demonstrates how to do. That is a very short list for a page that has already got the harder things right.
Who this is for
- Someone with genuine lash thinning who wants the approved drug at the approved strength and knows they are buying generic Latisse.
- Someone who has read about periorbital fat atrophy, understands it is usually reversible on stopping, and accepts the trade.
- Someone who will budget for a bottle every ten weeks rather than every twelve.
- Someone already using Alloy for hair loss who wants one prescriber across the whole picture.
- Someone who will use a fresh sterile applicator per eye, as supplied and as labelled.
- You have glaucoma or ocular hypertension, or use prostaglandin eye drops — this is the same drug class and that is a conversation for an ophthalmologist first.
- You would be troubled by a hollowed or deepened upper eyelid, which is the documented periorbital effect and the reason to know about it before starting rather than after.
- You are pregnant, planning pregnancy or breastfeeding. The page offers no position.
- You want it primarily for eyebrows and assumed the FDA approval covered that. It does not.
- You want the cheapest route to generic bimatoprost, which this is not.
Read about prostaglandin-associated periorbitopathy before you start — it is on this drug's own FDA label and nowhere on this page.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Alloy — Lash & Brow Serum Rx product page The $175 price billed as $58 a month, bimatoprost 0.03%, the 5 ml bottle and sterile applicators, the 'FDA Approved' badge, the brow marketing, the Carruthers and Fagien citations, the two safety FAQ questions, and the absence of periorbital, iris, pigmentation, glaucoma and pregnancy content in the visible copy. Read 28 July 2026.
- S-02LATISSE (bimatoprost ophthalmic solution) 0.03% — FDA label The approved indication for eyelash hypotrichosis, the applicator-based dosing, and the postmarketing periorbital and lid changes including periorbital fat atrophy and deepening of the eyelid sulcus.
- S-03LATISSE professional — dosing and application The 140 sterile applicators supplied with a 5 ml bottle and the one-applicator-per-eyelid instruction, which together give the 70-night figure in Fig. 2.
- S-04Prostaglandin Associated Periorbitopathy — EyeWiki The clinical picture — orbital fat atrophy, deepening of the upper eyelid sulcus, enophthalmos, ptosis — and its greater frequency with bimatoprost than with other prostaglandin analogues.
- S-05Decreased orbital fat and enophthalmos due to bimatoprost: quantitative MRI analysis (PLOS One) Imaging evidence quantifying orbital fat reduction attributable to bimatoprost.
- S-06Alloy — M4 Eye Cream Rx product page The same company's periorbital firming product, sold alongside a drug labelled for periorbital fat atrophy, with neither page mentioning the other.